Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C15H16N4O2.2ClH |
| Molecular Weight | 357.235 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.CC(CNC(=O)C1=CC=CN=C1)NC(=O)C2=CC=CN=C2
InChI
InChIKey=OBORDVXFXYGFAV-UHFFFAOYSA-N
InChI=1S/C15H16N4O2.2ClH/c1-11(19-15(21)13-5-3-7-17-10-13)8-18-14(20)12-4-2-6-16-9-12;;/h2-7,9-11H,8H2,1H3,(H,18,20)(H,19,21);2*1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C15H16N4O2 |
| Molecular Weight | 284.3131 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Nicaraven is a hydroxyl radical scavenger with antivasospastic and neuroprotective effects. Chugai (the Japanese subsidiary of Roche) is developing nicaraven (Antevas), a water-soluble antioxidant, for the potential treatment of disorders caused by acute cerebrovascular diseases. A registration application was filed in April 1995, and in April 2002, nicaraven was still awaiting registration in Japan. By August 2002, Chugai had filed an NDA in Japan for the additional indication of subarachnoidal bleeding.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effects of a hydroxyl radical scavenger on delayed ischemic neurological deficits following aneurysmal subarachnoid hemorrhage: results of a multicenter, placebo-controlled double-blind trial. | 1996 May |
|
| The potential benefits of nicaraven to protect against radiation-induced injury in hematopoietic stem/progenitor cells with relative low dose exposures. | 2014 Sep 26 |
|
| Nicaraven, a Potential Radioprotective Agent, has Very Limited Effects on the Survival of Cancer Cells and the Growth of Established Tumors. | 2017 Feb 22 |
Patents
Sample Use Guides
4 g nicaraven infused intravenously for 6-8 hours once a day
Route of Administration:
Intravenous
The antiplatelet activities in vitro of nicaraven were examined. The concentrations of nicaraven tested were 3.50 x 10(-5) mol/L, 1.75 x 10(-4) mol/L, 3.50 x 10(-4) mol/L, and 1.75 x 10(-3) mol/L, respectively. The maximum aggregation rate induced by adenosine diphosphate (ADP) was significantly inhibited by nicaraven at concentration ranges of 3.50 x 10(-4) mol/L or higher in the healthy volunteer platelets. The maximum aggregation rate induced by collagen was significantly inhibited by 1.75 x 10(-3) mol/L of nicaraven. Using platelets from patients with cerebral thrombosis, the maximum aggregation rate induced by ADP was significantly inhibited by 1.75 x 10(-3) mol/L of nicaraven. Furthermore, the maximum aggregation rate induced by collagen were significantly reduced by 1.75 x 10(-3) mol/L of nicaraven.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:04:46 GMT 2023
by
admin
on
Sat Dec 16 11:04:46 GMT 2023
|
| Record UNII |
K5U1Z432PH
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
20106710
Created by
admin on Sat Dec 16 11:04:46 GMT 2023 , Edited by admin on Sat Dec 16 11:04:46 GMT 2023
|
PRIMARY | |||
|
1158520-62-7
Created by
admin on Sat Dec 16 11:04:46 GMT 2023 , Edited by admin on Sat Dec 16 11:04:46 GMT 2023
|
PRIMARY | |||
|
K5U1Z432PH
Created by
admin on Sat Dec 16 11:04:46 GMT 2023 , Edited by admin on Sat Dec 16 11:04:46 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
